000K  utf8
1100  $c2021
1500  eng
2050  urn:nbn:de:gbv:8:3-2022-00251-4
2051  10.3390/biomedicines9101350
3000  Günther, Veronika
3010  Alkatout, Ibrahim
3010  Görg, Siegfried
3010  Maass, Nicolai Henning
3010  Meyerholz, Lisa
3010  von Otte, Sören
3010  Ziemann, Malte
4000  Live Birth Rates after Active Immunization with Partner Lymphocytes  [Günther, Veronika]
4209  Although many potential causes have been established for recurrent implantation failure (RIF) and recurrent miscarriage (RM), about 50% of these remain idiopathic. Scientific research is focused on immunological risk factors. In the present study, we aim to evaluate live birth rates after immunization with paternal lymphocytes (lymphocyte immunotherapy (LIT)). This retrospective study consisted of 148 couples with a history of RM and/or RIF. The women underwent immunization with lymphocytes of their respective partners from November 2017 to August 2019. Fifty-five patients (43%) had live births. Stratified by indication (RM, RIF, combined), live birth rates in the RM and the combined group were significantly higher than that in the RIF group (53%, 59% and 33%, respectively, p = 0.02). The difference was especially noticeable during the first 90 days after immunization (conception rate leading to live births: 31%, 23% and 8% for RM, the combined group and RIF, respectively; p = 0.005), while there was no difference between groups during the later follow-up. LIT was associated with high live birth rates, especially in women with recurrent miscarriage. In view of the limited data from randomized studies, LIT cannot be recommended as routine therapy. However, it may be considered in individual cases.
4950  https://doi.org/10.3390/biomedicines9101350$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2022-00251-4$xR$3Volltext$534
4961  https://macau.uni-kiel.de/receive/macau_mods_00002670
5051  610
5550  Immunization
5550  Implantation Failure
5550  Live Birth Rate
5550  Paternal Lymphocytes
5550  Recurrent Miscarriage